Compare MFIC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | RLAY |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2004 | 2020 |
| Metric | MFIC | RLAY |
|---|---|---|
| Price | $12.26 | $7.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $12.96 | ★ $16.00 |
| AVG Volume (30 Days) | 560.8K | ★ 2.1M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 12.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $324,678,000.00 | $8,355,000.00 |
| Revenue This Year | $10.19 | $20.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.47 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $10.18 | $1.78 |
| 52 Week High | $14.74 | $8.36 |
| Indicator | MFIC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 58.73 |
| Support Level | $12.06 | $7.23 |
| Resistance Level | $12.24 | $8.36 |
| Average True Range (ATR) | 0.19 | 0.51 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 91.01 | 69.18 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).